Sight SciencesNASDAQ: SGHT

The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve.

The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma.

Sight Sciences, Inc. (NASDAQ: SGHT) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET, featuring company representatives Philip Trip Taylor, Paul Badawi, Alison Bauerlein, and Matthew Link. Conference call participants include David Saxon, James Beers, and Thomas Stephan. Operator: Welcome to the Sight Sciences First Quarter 2024 Earnings Results Conference Call. Thank you for joining us.

Sight Sciences, Inc. (SGHT) reported a quarterly loss of $0.33 per share, slightly higher than the expected loss of $0.29 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.35 per share reported in the same quarter last year.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Tom Stephan - Stifel David Saxon - Needham & Company Margaret Kaczor - William Blair Operator Ladies and gentlemen, thank you for standing by and welcome to the Sight Sciences Fourth Quarter 2023 Earnings Results. [Operator Instructions] And please be advised that today's conference is being recorded.

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Margaret Kaczor - William Blair Kallum Titchmarsh - Morgan Stanley Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences' Third Quarter 2023 Earnings Results Call.